Sosei Confirms the Safety of SD118 in Two Phas...(i Tamura President & CEO of Sosei sa...),Health

Notes for Editors:

About Neuropathic Pain

Neuropathic pain is caused by a primary lesion or dysfunction in the nervous system and persists for months or years even after the initial damage had been healed. It can occur in a variety of traumatic diseases including spinal cord injury and nerve compression. Also, it is a common secondary symptom in diseases like diabetes, cancer and herpes zoster infection, and can occur after the use of cytotoxic drugs. The condition has a poor prognosis and is a significant cause of morbidity. The neuropathic pain market is forecast to reach US$5.5 billion by 2010. Although there is no single definition of neuropathic pain, approximately 26 million patients worldwide suffer from some forms of the condition (Espicom, 2005). The management of neuropathic pain is still a major challenge to the pharmacotherapy due to its unresponsiveness to most of the pain-killers, anticonvulsants, antidepressants and in some cases, opioids.

    Paraesthesia
    A transient sensation of numbness or tingling ["pins and needles"].

    Hypoaesthesia
    A reduced sense of touch.

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model based primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.so
'/>"/>